|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series C Convertible Preferred Stock (1) | $ 0.2 (2) | 10/29/2019 | P | 20 | (2) | (3) | Common Stock | 100,000 | $ 1,000 (4) | 350,000 (5) | D | ||||
| Series A Warrants (Right to Buy) (6) | $ 0.22 | 10/29/2019 | P | 100,000 | 10/29/2019 | 10/29/2021 | Common Stock | 100,000 | $ 1,000 (7) | 350,000 (5) | D | ||||
| Series B Warrants (Right to Buy) (8) | $ 0.22 | 10/29/2019 | P | 100,000 | 10/29/2019 | 10/29/2026 | Common Stock | 100,000 | $ 1,000 (9) | 350,000 (5) | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| Isett Thomas Francis 3rd C/O IBIO, INC. 600 MADISON AVENUE SUITE 1601 NEW YORK, NY 10022 |
X | |||
| /s/Thomas Isett | 11/05/2019 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The shares of Series C Convertible Preferred Stock, $0.001 par value (the "Series C Preferred Shares"), were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio"). |
| (2) | Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion. |
| (3) | The Series C Preferred Shares have no expiration date. |
| (4) | Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. |
| (5) | Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis. |
| (6) | The Series A Warrants were acquired by Mr. Isett in a public offering by iBio. |
| (7) | The Series A Warrants were sold together with Series C Preferred Shares and Series B Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. |
| (8) | The Series B Warrants were acquired by Mr. Isett in a public offering by iBio. |
| (9) | The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000. |